Format

Send to

Choose Destination
Expert Opin Drug Deliv. 2017 Jan;14(1):15-22. Epub 2016 Nov 18.

Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis.

Author information

1
a UCB Celltech , Slough , UK.
2
b UCB Pharma , Raleigh , NC , USA.
3
c UCB Pharma , Brussels , Belgium.
4
d Department of Rheumatology , University of Colorado School of Medicine , Denver , CO , USA.

Erratum in

Abstract

OBJECTIVES:

To compare the usability of a new certolizumab pegol (CZP) autoinjector with the adalimumab, etanercept, and golimumab devices in patients with rheumatoid arthritis.

METHODS:

Two identical studies were performed in 2013 and 2016; patients performed a simulated self-injection with the CZP autoinjector and the most up-to-date device versions at the time in a randomized, consecutive sequence. The primary end point was the ranking of the four autoinjectors in order of preference. Device usability and intuitiveness were assessed across a range of secondary and exploratory end points.

RESULTS:

The 2013 and 2016 study populations included 76 patients each; a significant majority (2013: 67%; 2016: 59%) ranked the CZP autoinjector as their most preferred device (p < 0.001). Most patients agreed that the CZP autoinjector was easier to use, start, and manipulate, and were more willing to use it than the comparator devices (p < 0.001 for all pairwise comparisons with CZP). Likert score differences also favored the CZP autoinjector regarding how easy it was to determine injection completion. The CZP autoinjector was associated with a low rate of use error.

CONCLUSIONS:

In both studies, the CZP autoinjector was the preferred choice compared to the alternative devices and was associated with a high level of patient satisfaction.

KEYWORDS:

Autoinjector; certolizumab pegol; patient preference; rheumatoid arthritis; usability

PMID:
27801596
DOI:
10.1080/17425247.2016.1256283
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center